Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.46 |
| ▸ | ACACA | Q13085 | 11/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4589336 | 0.89 | ACACB (0.42) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL8866508 | 0.83 | ACACB (0.56) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL8867021 | 0.81 | ACACB (0.50) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL8866482 | 0.79 | ACACB (0.47) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL21014288 | 0.75 | RIPK1 (0.33) | — | |
| SCHEMBL8867046 | 0.74 | ACACB (0.45) | ACACBACACAIRAK1 | |
| SCHEMBL8866425 | 0.73 | ACACB (0.42) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL21033178 | 0.70 | RIPK1 (0.37) | — | |
| SCHEMBL9005377 | 0.70 | CKS1B (0.52) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL21033955 | 0.70 | RIPK1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207650-A1 | Chemical Compounds 636 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207650-A1 | Chemical Compounds 636 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207650-A1 | Chemical Compounds 636 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008084240-A1 | CHEMICAL COMPOUNDS 636 : PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084240-A1 | CHEMICAL COMPOUNDS 636 : PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207650-A1 | Chemical Compounds 636 | PDE4A, PDE3B, PDE3A | ACACB 2894/4885ACACA 2423/4885CKS1B 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.